{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:15:32Z","timestamp":1788567332308,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","award":["BOF22DOC18"],"award-info":[{"award-number":["BOF22DOC18"]}],"id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jns.2026.125756","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:40:14Z","timestamp":1768376414000},"page":"125756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews"],"prefix":"10.1016","volume":"481","author":[{"given":"Sofie","family":"Aerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Geys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Severijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Alkhawajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Boyko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magd","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125756_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.msard.2017.07.003","article-title":"Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?","volume":"17","author":"Fern\u00e1ndez","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2026.125756_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review(\u2730)","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jns.2026.125756_bb0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0020","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2026.125756_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2026.125756_bb0030","article-title":"Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis","volume":"9","author":"Reeve","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2026.125756_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105755","article-title":"Clinical risk stratification: development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis","volume":"89","author":"Fuchs","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2026.125756_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106423","article-title":"Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis","volume":"98","author":"Jelgerhuis","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2026.125756_bb0045","first-page":"269","article-title":"Differences between general neurologists and multiple sclerosis specialists in the Management of Multiple Sclerosis Patients: a National Survey","volume":"56","author":"K\u00fcrt\u00fcnc\u00fc","year":"2019","journal-title":"Noro Psikiyatr. Ars."},{"key":"10.1016\/j.jns.2026.125756_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103404","article-title":"Factors associated with treatment escalation among MS specialists and general neurologists: results from an international cojoint study","volume":"58","author":"Saposnik","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2026.125756_bb0055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1191\/1352458504ms1112oa","article-title":"Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis","volume":"10","author":"Heesen","year":"2004","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.jns.2026.125756_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059042","article-title":"Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool","volume":"8","author":"Heesen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jns.2026.125756_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101445","article-title":"Do people with multiple sclerosis want to discuss their long-term prognosis? A nationwide study in Argentina","volume":"37","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2026.125756_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193407","article-title":"Do people with multiple sclerosis want to know their prognosis? A UK nationwide study","volume":"13","author":"Dennison","year":"2018","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.jns.2026.125756_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09637","article-title":"Neurologists\u2019 views on patient reported outcomes in multiple sclerosis care","volume":"8","author":"Reitzel","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jns.2026.125756_bb0080","first-page":"92","article-title":"The perspectives of neurologists on positron emission tomography utility in multiple sclerosis: a qualitative study","author":"Ezzat","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2026.125756_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15020069","article-title":"Attitudes of neurologists toward serum Neurofilament light-chain testing in the Management of Relapsing-Remitting Multiple Sclerosis with cognitive impairment","volume":"15","author":"Garc\u00eda-Dom\u00ednguez","year":"2025","journal-title":"J. Pers. Med."},{"issue":"2","key":"10.1016\/j.jns.2026.125756_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001269","article-title":"Organisational impact and patient management models for biomarker integration in multiple sclerosis care in Italy: the 0Tolerance project","volume":"7","author":"Ragonese","year":"2025","journal-title":"BMJ Neurol. Open."},{"issue":"2","key":"10.1016\/j.jns.2026.125756_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.jns.2026.125756_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7224\/1537-2073.2015-062","article-title":"The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals\u2019 experiences","volume":"18","author":"Davies","year":"2016","journal-title":"Int. J. MS Care."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","article-title":"The qualitative content analysis process","volume":"62","author":"Elo","year":"2008","journal-title":"J. Adv. Nurs."},{"issue":"6","key":"10.1016\/j.jns.2026.125756_bb0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int. J. Qual. Health Care"},{"issue":"4","key":"10.1016\/j.jns.2026.125756_bb0115","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","article-title":"A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition","volume":"268","author":"Inojosa","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-8-55","article-title":"Disability status and quality of life in multiple sclerosis: non-linearity of the expanded disability status scale (EDSS)","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jns.2026.125756_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102485","article-title":"Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration","volume":"46","author":"Ellenberger","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.jns.2026.125756_bb0130","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1177\/1352458519887343","article-title":"Predicting disability progression in multiple sclerosis: insights from advanced statistical modeling","volume":"26","author":"Pellegrini","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0272989X17724434","article-title":"Whose preferences matter? A patient-centered approach for eliciting treatment goals","volume":"38","author":"Col","year":"2018","journal-title":"Med. Decis. Making"},{"issue":"3","key":"10.1016\/j.jns.2026.125756_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/CPJ.0000000000000449","article-title":"Identifying priority outcomes that influence selection of disease-modifying therapies in MS","volume":"8","author":"Day","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jns.2026.125756_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PPA.S268829","article-title":"Disease progression in multiple sclerosis: a literature review exploring patient perspectives","volume":"15","author":"Celius","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jns.2026.125756_bb0150","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1040-8428(13)70005-2","article-title":"An alternative view on the task of prognosis","volume":"84","author":"Bernegger","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jns.2026.125756_bb0155","first-page":"53","article-title":"The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study","author":"Tur","year":"2025","journal-title":"The Lancet Regional Health \u2013 Europe"},{"issue":"10076","key":"10.1016\/j.jns.2026.125756_bb0160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2026.125756_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"10","key":"10.1016\/j.jns.2026.125756_bb0170","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125756_bb0175","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","article-title":"Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.125756_bb0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.nrl.2023.06.001","article-title":"Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023","volume":"39","author":"Meca-Lallana","year":"2024","journal-title":"Neurologia (Engl Ed)."},{"key":"10.1016\/j.jns.2026.125756_bb0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12883-016-0639-7","article-title":"Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach","volume":"16","author":"Ziemssen","year":"2016","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.125756_bb0190","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/1352458518807076","article-title":"Multidisciplinary data infrastructures in multiple sclerosis: why they are needed and can be done!","volume":"25","author":"Peeters","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2026.125756_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103885","article-title":"The Sylvia Lawry Centre for multiple sclerosis research (SLCMSR)\u2013\u2013critical review facing the 20 anniversary","volume":"63","author":"Heesen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.125756_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102512","article-title":"Clinical outcome measures in multiple sclerosis: a review","volume":"19","author":"Inojosa","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0210","doi-asserted-by":"crossref","first-page":"18238","DOI":"10.1038\/s41598-022-23088-x","article-title":"Patient\u2019s perspective in clinical practice to assess and predict disability in multiple sclerosis","volume":"12","author":"Gil-Perotin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2026.125756_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991291","article-title":"Using personalized prognosis in the treatment of relapsing multiple sclerosis: a practical guide","volume":"13","author":"Van Wijmeersch","year":"2022","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.jns.2026.125756_bb0220","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.3390\/jcm11154401","article-title":"MSProDiscuss\u2122 clinical decision support tool for identifying multiple sclerosis progression","volume":"11","author":"Ziemssen","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jns.2026.125756_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106278","article-title":"Development and validation of a scoring system for predicting disease activity in treatment-naïve patients with relapsing-remitting multiple sclerosis","volume":"94","author":"Zakaria","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2026.125756_bb0230","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nicl.2016.07.015","article-title":"PREVAIL: predicting recovery through estimation and visualization of active and incident lesions","volume":"12","author":"Dworkin","year":"2016","journal-title":"NeuroImage: Clinical"},{"issue":"Supplement_4","key":"10.1016\/j.jns.2026.125756_bb0235","doi-asserted-by":"crossref","DOI":"10.1093\/eurpub\/ckz185.205","article-title":"Geographical variations in access to expert centers for multiple sclerosis in France","volume":"29","author":"Leray","year":"2019","journal-title":"Eur. J. Public Health"},{"key":"10.1016\/j.jns.2026.125756_bb0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fneur.2017.00065","article-title":"Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS)","volume":"8","author":"Saposnik","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.125756_bb0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/PPA.S440410","article-title":"Shared decision-making in the treatment of multiple sclerosis: results of a cross-sectional, real-world survey in Europe and the United States","volume":"18","author":"Keenan","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jns.2026.125756_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1446748","article-title":"A future of AI-driven personalized care for people with multiple sclerosis","volume":"15","author":"Praet","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.125756_bb0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: an experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods"},{"key":"10.1016\/j.jns.2026.125756_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc. Sci. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:22:40Z","timestamp":1774275760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"alternative-id":["S0022510X26000377"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125756","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125756"}}